Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults
Garau, Javier, Twynholm, Monique, Garcia-Mendez, Elena, Siquier, Bartolome, Rivero, Antonio
Published in Journal of antimicrobial chemotherapy (01.11.2003)
Published in Journal of antimicrobial chemotherapy (01.11.2003)
Get full text
Journal Article